Biological, electrical and echocardiographic indices versus cardiac magnetic resonance imaging in diagnosing left ventricular hypertrophy

Hypertension Research

Volumn 37, Issue 5, 2014, Pages 444-451

  Courand, Pierre Yves ^a,b,c   Gaudebout, Nathalie ^c   Mouly Bertin, Carine ^a   Thomson, Vivien ^a   Fauvel, Jean Pierre ^b,c,d   Bricca, Giampiero ^b,c   Lantelme, Pierre ^a,b,c  

^a CROIX ROUSSE HOSPITAL   (France)

^b University Lyon 1   (France)

^c Service de cardiologie Hôpital Nord Ouest   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

cardiac magnetic resonance imaging; hypertension; left ventricular hypertrophy; NT proBNP; transthoracic echocardiography

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HORMONE ACTION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MALE; RECEIVER OPERATING CHARACTERISTIC; SCIENTIFIC LITERATURE; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; BLOOD; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; BLOOD PRESSURE MONITORING, AMBULATORY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY;

EID: 84899887555     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.147     Document Type: Article

References (40)

1. Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, Castelli WP. Risk of ventricular arrhythmias in left ventricular hypertrophy: The Framingham Heart Study. Am J Cardiol 1987; 60: 560-565
2. McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med 1987; 317: 787-792
3. Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Zampi I, Battistelli M, Gattobigio R, Sacchi N, Porcellati C. Association between persistent pressure overload and ventricular arrhythmias in essential hypertension. Hypertension 1996; 28: 284-289
4. Alfakih K, Walters K, Jones T, Ridgway J, Hall AS, Sivananthan M. New gender specific partition values for ECG criteria of left ventricular hypertrophy recalibration against cardiac MRI. Hypertension 2004; 44: E13
5. Korner PI, Jennings GL. Assessment of prevalence of left ventricular hypertrophy in hypertension. J Hypertens 1998; 16: 715-723
6. Missouris CG, Forbat SM, Singer DR, Markandu ND, Underwood R, MacGregor GA. Echocardiography overestimates left ventricular mass: A comparative study with magnetic resonance imaging in patients with hypertension. J Hypertens 1996; 14: 1005-1010
7. Myerson SG, Montgomery HE, World MJ, Pennel DJ. Left ventricular mass: Reliability of M-mode and 2-dimensional echocardiographic formulas. Hypertension 2002; 40: 673-678
8. Gosse P, Cremer A, Vircoulon M, Coulon P, Jan E, Papaioannou G, Yeim S. Prognostic value of the extent of left ventricular hypertrophy and its evolution in the hypertensive patient. J Hypertens 2012; 30: 2403-2409
9. Katz J, Milliken MC, Stray-Gundersen J, Buja LM, Parkey RW, Mitchell JH, Peshock RM. Estimation of human myocardial mass with MR imaging. Radiology 1988; 169: 495-498
10. Bottini PB, Carr AA, Prisant LM, Flickinger FW, Allison JD, Gottdiener JS. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patients. Am J Hypertens 1995; 8: 221-228
11. Myerson SG, Bellenger NG, Pennel DJ. Assessment of left ventricular mass by cardiovascular imaging resonance. Hypertension 2002; 39: 750-755
12. Mouly-Bertin C, Bissery A, Milon H, Dzudie A, Rabilloud M, Bricca G, Vincent M, Lantelme P. N-Terminal pro-brain natriuretic peptide-A promising biomarker for the diagnosis of left ventricular hypertrophy in hypertensive women. Arch Cardiovasc Dis 2008; 101: 307-315
13. Andrade H, Morillas P, Castillo J, Roldán J, Mateo I, Agudo P, Quiles J, Bertomeu-Martínez V. Diagnostic accuracy of NT-proBNP compared with electrocardiography in detecting left ventricular hypertrophy of hypertensive origin. Rev Esp Cardiol 2011; 64: 939-941
14. Morillas P, Castillo J, Nunez D, Guillen S, Maceira A, Rivera M, Bertomeu V. Usefulness of NT-proBNP level for diagnosing left ventricular hypertrophy in hypertensive patients. A cardiac magnetic resonance study. Rev Esp Cardiol 2008; 61: 972-975
15. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F 2013ESH/ ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281-1357
16. Sokolow M, Lyon T. The ventricular complex in left ventricular hypertrophy using a new electrocardiographic left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949; 37: 161-186
17. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: Validation with autopsy findings. Circulation 1987; 75: 565-572
18. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995; 25: 417-423
19. Gosse P, Jan E, Coulon P, Cremer A, Papaioannou G, Yeim S. ECG detection of left ventricular hypertrophy: The simple, the better?. J Hypertens 2012; 30: 990-996
20. Verdecchia P, Angeli F, Cavallini C, Mazzotta G, Repaci S, Pede S, Borgioni C, Gentile G, Reboldi G. The voltage of R wave in lead aVL improves risk stratification in hypertensive patients without ECG left ventricular hypertrophy. J Hypertens 2009; 27: 1697-1704
21. Fradley MG, Larson MG, Cheng S, McCabe E, Coglianese E, Shah RV, Levy D, Vasan RS, Wang TJ. Reference limits for N-Terminal-pro-B-Type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol 2011; 108: 1341-1345
22. Alehagen U, Goetze JP, Dahlström U. Reference intervals and decision limits for B-Type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. Clin Chim Acta 2007; 382: 8-14
23. Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-Terminal pro-brain natriuretic peptide?. How well does this normal range screen for cardiovascular disease?. Eur Heart J 2005; 26: 2269-2276
24. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension 1987; 9: 1119-1126
25. De Simone G, Devereux RB, Daniels SR, Koren MJ, Meyer RA, Laragh JH. Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25: 1056-1062
26. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J 2012; 33: 1787-1847
27. Alfakih K, Reid S, Hall A, Sivananthan MU. The assessment of left ventricular hypertrophy in hypertension. J Hypertens 2006; 24: 1223-1230
28. Sandstede J, Lipke C, Beer M, Hofmann S, Pabst T, Kenn W, Neubauer S, Hahn D. Age and gender-specific differences in left and right ventricular cardiac function and mass determined by cine magnetic resonance imaging. Eur Radiol 2000; 10: 438-442
29. Kohno M, Horio T, Yokokawa K, Murakawa K, Yasunari K, Akioka K, Tahara A, Toda I, Takeuchi K, Kurihara N, Takeda T. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92: 29-34
30. Nishikimi T, Yoshihara F, Morimoto A, Ishikawa K, Ishimitsu T, Saito Y, Kangawa K, Matsuo H, Omae T, Matsuoka H. Relation between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22-30
31. Kohno M, Horio T, Yokokawa K, Yasunari K, Ikeda M, Minami M, Kurihara N, Takeda T. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: Changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 1995; 98: 257-265
32. Almeida P, Azevedo A, Rodrigues R, Dias P, Frioes F, Vazquez B, Abreu-Lima C, Bettencourt P, Barros H. B-Type natriuretic peptide and left ventricular hypertrophy in hypertensive patients. Rev Port Cardiol 2003; 22: 327-336
33. Yasumoto K, Takata M, Ueno H, Tomita S, Tomoda F, Inoue H. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension. Am J Hypertens 1999; 12: 921-924
34. Nakamura M, Tanaka F, Ionezawa S, Satou K, Nagano M, Hiramori K. The limited value of plasma B-Type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am J Hypertens 2003; 16: 1025-1029
35. Bricca G, Lantelme P. Natriuretic peptides: Ready for prime-Time in hypertension. Arch Cardiovasc Dis 2011; 104: 403-409
36. Throughton RW, Richards AM, Yandle TG, Frampton CM, Nicholls MG. The effects of medication on circulating levels of cardiac natriuretic peptides. Ann Med 2007; 39: 242-260
37. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt PR. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: A LIFE substudy. J Hypertens 2005; 23: 1083-1090
38. Paget V, Legedz L, Gaudebout N, Girerd N, Bricca G, Milon H, Vincent M, Lantelme P. N-Terminal pro-brain natriuretic peptide: A powerful predictor of mortality in hypertension. Hypertension 2011; 57: 702-709
39. Spranger CB, Ries AJ, Berge CA, Radford NB, Victor RG. Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med 2004; 117: 14-18
40. Raymond I, Groenning BA, Hildebrandt PR, Nilson JC, Baumann M, Trawinski J, Pedersen F. The influence of age, sex and other variables on the plasma level of N-Terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745-775